Hilleman is proud to have built a portfolio of advanced product candidates to meet global public health needs, particularly in low- and middle-income countries.
HillChol® is Hilleman Laboratories’ flagship vaccine. It is a best-in-class oral cholera vaccine developed as a two-dose liquid delivery. Phase III clinical trials of the vaccine have concluded and is pending approval and licensure in certain territories. As a single strain vaccine, the cost of production is significantly lower and when made available, the vaccine will have a huge positive impact in countries such as India, Bangladesh and GAVI countries where cholera is endemic.
ERVEBO® is an Ebola vaccine used in ring vaccination strategies in Central and West Africa to tackle recent outbreaks since 2014. In partnership with Merck Research Labs, ERVEBO® is being improved for a standard thermostability profile (4–8°C) compared to the current (-80°C). The improvements are aimed at making the vaccine more affordable, and increasing production volumes to provide wider, more equitable access.
World’s first scientific demonstration on an LPS conjugate vaccine for Coxiella burnetii which causes Q Fever, an epidemic that is considered an occupational hazard among laboratory, livestock, and veterinary workers and is also considered a bioterrorism agent.
A pentavalent meningitis vaccine which has the broadest coverage against the main circulating vaccine strains that cause infection and disease, with several granted patents in developed and developing countries.
An optimized high-yield yeast-based platform for an alternative cost-effective way to produce recombinant human serum albumin (rHSA) for use as an excipient in vaccines and therapeutics.